TECTONIC THERAPEUTIC, INC. Financing Receivable, Reclassification to Held-for-sale
TECTONIC THERAPEUTIC, INC. (TECX) reported Financing Receivable, Reclassification to Held-for-sale of $2.29 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Notes › and Others
us-gaap:FinancingReceivableReclassificationToHeldForSale · last filed 2023-11-09
| Period end | Financing Receivable, Reclassification to Held-for-sale 9 month | Financing Receivable, Reclassification to Held-for-sale 12 month |
|---|---|---|
| 2023-09-30 | $2.29M 10-Q · filed 2023-11-09 | |
| 2022-12-31 | $0.00 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |